SCHEDULE: Oramed Pharmaceuticals Discloses 9.9% Scilex Stake

Oramed Pharmaceuticals Inc. has disclosed a 9.9% beneficial ownership stake in Scilex Holding Co, primarily through exercisable warrants.

Summary

• Oramed Pharmaceuticals Inc. reported beneficial ownership of 764,277 shares of Scilex Holding Co common stock.
• This ownership represents 9.9% of Scilex Holding Co's outstanding common stock.
• The beneficially owned shares are primarily comprised of common stock issuable upon the exercise of warrants, which are exercisable within 60 days of the filing date.
• The calculation of the 9.9% stake is based on 6,955,697 shares of Scilex Holding Co common stock outstanding as of August 8, 2025, plus the 764,277 warrant shares held by Oramed.
• Oramed Pharmaceuticals Inc. holds sole voting power and sole dispositive power over all 764,277 shares.

Sentiment

Score: 7

Explanation: The filing indicates a significant, near 10% stake by Oramed Pharmaceuticals in Scilex Holding Co, which is generally viewed as a positive signal of confidence from a substantial investor. The acquisition through warrants suggests a strategic, potentially long-term interest.

Positives

• Oramed Pharmaceuticals Inc.'s significant 9.9% beneficial ownership stake in Scilex Holding Co indicates a substantial investment and potential confidence in the company's future prospects.
• The stake is largely derived from warrants, suggesting a strategic entry point for Oramed Pharmaceuticals Inc. into Scilex Holding Co.

Management Comments

• Avraham Gabay, Chief Financial Officer of Oramed Pharmaceuticals Inc., certified that the information set forth in the statement is true, complete, and correct to the best of his knowledge and belief.

Industry Context

Schedule 13G filings are standard disclosures for passive investors who acquire beneficial ownership of more than 5% of a company's voting stock. These filings provide transparency regarding significant ownership stakes, indicating a notable investment by one entity in another, which can be a signal of confidence or strategic interest within the pharmaceutical and biotechnology sectors.

Stakeholder Impact

• Shareholders of Scilex Holding Co may view Oramed Pharmaceuticals Inc.'s significant 9.9% stake as a positive indicator of institutional confidence and potential future collaboration or strategic alignment.
• The disclosure provides increased transparency regarding the ownership structure of Scilex Holding Co.

Key Dates

Keywords

Scilex Holding Co, Oramed Pharmaceuticals, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Warrants, Pharmaceuticals, Biotechnology